Gland Pharma Limited Announces Key Governance Changes: Directorship Reappointments and Resignations
Gland Pharma Limited's Board of Directors met on June 15, 2026, approving several significant changes concerning its directorial strength. The outcomes included the re-appointment of an Independent Director, the addition of a new Additional Director, and the acceptance of a resignation due to potential conflicts of interest.The Board meeting considered and approved the re-appointment of Mr. Udo Jahannes Vetter as an Independent Director for a second term of five consecutive years. His tenure is effective from July 21, 2026, through July 20, 2031.
Furthermore, Mr. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent Director) of the company, effective June 15, 2026. Mr. Keller is currently an Independent Director on the Board of Wuxi Biologics Limited.
Resignation and Succession at Gland Pharma
The meeting also addressed the resignation of Mr. Satyanarayana Murthy Chavali, an Independent Director. The resignation was accepted with effect from the close of business hours on June 15, 2026. Mr. Chavali cited a potential conflict of interest as the reason for his decision. This potential conflict relates to a company where he serves as Promoter and Director that proposes entering a business segment similar or overlapping with activities Gland Pharma Limited is contemplating in the future.Following this change, Mr. Essaji Goolam Vahanvati was appointed as a Director on the Board of Gland Pharma International Pte. Ltd (a Material Subsidiary of the Company), effective June 15, 2026.
Board Composition of Gland Pharma International Pte. Ltd
The composition of the Board of Directors for Gland Pharma International Pte. Ltd, as of June 15, 2026, is detailed below:| Director Name |
|---|
| Mr. Srinivas Sadu |
| Mr. Essaji Goolam Vahanvati |
| Mr. Wu Rong (Mr. Raymond Wu) |
| Ms. Liao Rong (Ms. Carol Rong) |
Committee Realignment
In light of the changes in the Board of Directors, the committees within the company were realigned, effective June 15, 2026.Key updates across various board committees include:
- Audit Committee: Mr. Essaji Goolam Vahanvati was appointed as the Chairman of the Committee.
- Nomination & Remuneration Committee: Mr. Udo J Vetter has been appointed as the Chairman of the Committee.
- Stakeholders' Relationship Committee & Share Transfer Committee: Mr. Udo J Vetter was appointed as the Chairman of the Committee, replacing Mr. C.S.N. Murthy.
- ESOP Compensation Committee: Mr. Udo J Vetter was appointed as the Chairman and Mr. Srinivas Sadu was appointed as a member, both roles involving changes from previous leadership structures.
The Board meeting commenced at 15:00 Hrs. IST and concluded at 15:50 Hrs. IST.
GLAND Stock Price Movement
Shares of Gland Pharma Limited on Monday slipped by 2.40% to settle at ₹2,213.1, as investors reacted negatively to market pressures. Trading volume reached 555,244 shares, with the stock dipping all day to a low of ₹2,190.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.